Schiff Hardin LLP today announced the addition of Kevin M. Nelson as a partner in its rapidly growing Intellectual Property Group. Nelson has joined the Chicago office, where he is a member of the firm’s Pharmaceuticals and Biologics Patent Team. Nelson has more than 15 years of experience representing generic drug manufacturers in patent litigation brought under the Hatch-Waxman amendments.
“Kevin brings significant experience in complex pharmaceutical patent litigation, which is increasingly one of our most in-demand services,” said Imron T. Aly, a partner who co-leads the firm’s Intellectual Property Group and co-chairs the Pharmaceuticals and Biologics Patent Litigation Team.
“In the past 12 months alone, we have been at eight pharma trials and evidentiary hearings, so Kevin’s arrival is well-timed,” said Partner Sailesh K. Patel, co-leader of the firm’s Intellectual Property Group and co-chair of the Pharmaceuticals and Biologics Patent Litigation Team. “We are thrilled to welcome him to our team.”
Nelson has litigated cases involving patents purportedly covering widely known pharmaceutical products and methods of using such products. He has represented clients on regulatory matters before the U.S. Food and Drug Administration (FDA) and has counseled clients on biosimilar applications and strategy. Along with extensive work in the pharmaceutical sector, Nelson has also handled cases involving trademark and copyright infringement, false or unfair advertising, and unfair competition claims.
“I am excited about joining Schiff Hardin to work with leading lawyers who are at the forefront of helping clients develop and market pharmaceutical and biosimilar products,” said Nelson. “This is a great opportunity to become part of an outstanding team that is one of the world’s most active and successful in Hatch-Waxman and biosimilars law.”
Nelson is a frequent invited speaker on intellectual property and patent law issues both domestically and internationally. He also has presented on document retention and e-discovery issues in federal litigation. Nelson was formerly a partner in the Chicago office of Duane Morris LLP, where he was co-head of its Intellectual Property: Generic and Biosimilar Pharmaceuticals Practice.
Schiff Hardin’s Intellectual Property Group represents a wide range of domestic and international clients from a diverse group of industries on the full spectrum of copyright, trademark and patent issues and disputes. As a leader in biologics and biosimilar patent litigation, Schiff Hardin represents companies whose products are often challenged under dozens of patents and provoke litigation under the Biologics Price Competition and Innovation Act.
To date, the firm’s IP group has represented more than a dozen generic pharmaceutical companies on more than 100 products in abbreviated new drug application (ANDA) patent litigations, as well as other FDA applications. The firm has successfully litigated many cases in key national jurisdictions, as well as won in appellate cases before the Federal Circuit.
Source: www.schiffhardin.com
